Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,636 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.
Bhatt RS, Berjis A, Konge JC, Mahoney KM, Klee AN, Freeman SS, Chen CH, Jegede OA, Catalano PJ, Pignon JC, Sticco-Ivins M, Zhu B, Hua P, Soden J, Zhu J, McDermott DF, Arulanandam AR, Signoretti S, Freeman GJ. Bhatt RS, et al. Among authors: zhu b, zhu j. Cancer Immunol Res. 2021 Feb;9(2):156-169. doi: 10.1158/2326-6066.CIR-20-0315. Epub 2020 Nov 23. Cancer Immunol Res. 2021. PMID: 33229411 Free PMC article.
PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface.
Chaudhri A, Xiao Y, Klee AN, Wang X, Zhu B, Freeman GJ. Chaudhri A, et al. Among authors: zhu b. Cancer Immunol Res. 2018 Aug;6(8):921-929. doi: 10.1158/2326-6066.CIR-17-0316. Epub 2018 Jun 5. Cancer Immunol Res. 2018. PMID: 29871885 Free PMC article.
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.
Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, Eisenhaure TM, Pendergraft WF 3rd, Hua P, Pham HC, Bu X, Zhu B, Hacohen N, Fritsch EF, Boussiotis VA, Wu CJ, Freeman GJ. Mahoney KM, et al. Among authors: zhu b. Cancer Immunol Immunother. 2019 Mar;68(3):421-432. doi: 10.1007/s00262-018-2282-1. Epub 2018 Dec 18. Cancer Immunol Immunother. 2019. PMID: 30564891 Free PMC article.
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses.
Bu X, Juneja VR, Reynolds CG, Mahoney KM, Bu MT, McGuire KA, Maleri S, Hua P, Zhu B, Klein SR, Greenfield EA, Armand P, Ritz J, Sharpe AH, Freeman GJ. Bu X, et al. Among authors: zhu b. Cancer Immunol Res. 2021 Dec;9(12):1465-1475. doi: 10.1158/2326-6066.CIR-21-0493. Epub 2021 Oct 11. Cancer Immunol Res. 2021. PMID: 34635486 Free PMC article.
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.
Naito M, Hainz U, Burkhardt UE, Fu B, Ahove D, Stevenson KE, Rajasagi M, Zhu B, Alonso A, Witten E, Matsuoka K, Neuberg D, Duke-Cohan JS, Wu CJ, Freeman GJ. Naito M, et al. Among authors: zhu b. Cancer Immunol Immunother. 2013 Feb;62(2):347-57. doi: 10.1007/s00262-012-1331-4. Epub 2012 Aug 25. Cancer Immunol Immunother. 2013. PMID: 22926059 Free PMC article.
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.
Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le Gall S, Waring MT, Ahern R, Moss K, Kelleher AD, Coffin JM, Freeman GJ, Rosenberg ES, Walker BD. Kaufmann DE, et al. Among authors: zhu b. Nat Immunol. 2007 Nov;8(11):1246-54. doi: 10.1038/ni1515. Epub 2007 Sep 30. Nat Immunol. 2007. PMID: 17906628
10,636 results
You have reached the last available page of results. Please see the User Guide for more information.